Anto Ignat Stany M, Susan Dsouza, Peter George


Introduction: Guillain-Barré syndrome (GBS) is a demyelinating polyneuropathy characterized by progressive symmetric motor weakness with
reduced or absent deep tendon reflexes. Clinical features, CSF analysis and electro-diagnostic studies aids in diagnosis.
Methods: This study included patients with GBS admitted to a tertiary care center in South India for 3 years from June 2013. Data pertaining to
history, examination and laboratory reports were obtained from medical records and captured into a pre-formatted data sheet and was analysed
using SPSS v20.0.
Results: Among the 48 patients (31 males, 17 females) included in this study, 31% had no antecedent illness, while 30% had history of a nonspecific
febrile illness prior to onset of symptoms. The mean duration between the antecedent event and onset of weakness was 6.75 days. Areflexia
and quadriparesis were the most common clinical features. The incidence of cranial nerve involvement was highly variable, facial nerve being the
commonest. Ten patients progressed to develop respiratory paresis and needed mechanical ventilation. Acute inflammatory demyelinating
polyneuropathy (AIDP) was the commonest variant (57%), followed by acute motor axonal neuropathy (AMAN, 21%) and acute sensorimotor
axonal neuropathy (AMSAN, 19%). There was no statistically significant association between age, gender, type of GBS, mode of treatment and
final outcome, though IvIg and plasmapheresis decreased the mean duration of hospital stay by approximately 10 days compared to those managed
conservatively alone.
Conclusion: Areflexia and quadriparesis were the commonest presenting features. IVIg and plasmapheresis hasten recovery but did not alter the


Guillain-Barré syndrome, Clinical profile, AIDP, AMAN, AMSAN, Miller-Fisher Variant, Adults, IvIg, Plasmapharesis.

Full Text:



Yuki N, Hartung H-P. Guillain–Barré Syndrome. N Engl J Med 2012; 366(24):2294-304.

Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008; 70(18):1608-13.

Desforges JF, Ropper AH. The Guillain–Barré Syndrome. N Engl J Med 1992; 326(17):1130-6.

Patwa HS, Chaudhry V, Katzberg H, So YT, Rae-Grant a D, So YT. Evidence-based guideline : Intravenous immunoglobulin in the treatment of neuromuscular disorders. Neurology 2012; 78:1009-15.

Hughes RAC, Wijdicks EFM, Benson E, Cornblath DR, Hahn AF, Meythaler JM, et al. Supportive Care for Patients With Guillain-Barré Syndrome. Arch Neurol 2005; 62(8):1194.

Ropper AH, Brown RH . Adams and Victor’s Principles of Neurology. 9th ed. New York: Mc Graw-Hill 2005; 1117-27.

Guo-Xin J. GBS in Sweden from clinical epidemiology to public health surveillance. J. Neurol1996; 75:123-29.

Hadden RDM, Hughes RAC. GBS recent advances. Arch Neurol 2008; 41:511-4.

Loffel VB, Rossi LN, Mumenyhaler M. The Landry Gullian Barre Syndrome complication prognosis and natural History of 123 cases. J Neural SG 1977; 33:71-9.

Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre Syndrome. J Assoc Physicians India 2013; 61(3):168-72.

Ropper AH. Guillain- Barre syndrome variants in Emilia – Ramagna, Italy, 1992-93: Incidence, clinical features, and prognosis. J Neurol NeurosurgPsychiatry 1998; 65:218-24.

Jacobs BC, van derMeche FGA, Herbrink P, Schmitz PIM, de Klerk MA, van Doorn PA. The spectrum of antecedent infections in Guillain Barre Syndrome case control study. Arch Neurol 1988; 45:104-47.

Avila-Funes JA, Mariona-Montero VA, Melano-Carranza E. Guillain-Barre syndrome: etiology and pathogenesis. Rev Invest Clin 2002; 54(4):357-63.

Asbury MIC.New Concepts of GBS. J Child Neurology 2000;75:1013-9.

Louie M, Gilchrist JM, Woodward G. 5 years Rhod Island Hospital Experience GBS. Lancet Neurol2000; 40:501-11.

Akbayram S, Dogan M, Akgün C, Peker E, Sayin R, Aktar F et al. Clinical features and prognosis with Guillain-Barré syndrome. Ann Indian Acad Neurol 2011;14(2):98-102.

Yadegari S, Nafissi S, Kazemi N. Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome. Iran J Neurol. 2014;13(3):138-43.

Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014;50(5):780-4.

Sater RA, Rostami A. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Neurology 1998;51(6 Suppl 5):S9-15.

Van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immuneglobulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-BarréStudy Group. N Engl J Med. 1992;326(17):1123-9.

Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology. 1985;35(8):1096-104.

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol. 1987;22(6):753-61.

Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491-510.

Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM et al; Multidisciplinary Consensus Group. Supportive care forpatients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194-8


  • There are currently no refbacks.